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Introduction
Psychological well-being serves a crucial role in the health and productivity of humanbeings in our society.1 Individuals with psychological conditions can experience symptoms
which include the inability to distinguish fiction from reality, extreme thoughts of sadness, and
intense anxiety.2 When an individual’s world becomes altered, their ability to thrive and flourish
independently becomes tarnished. Individuals with psychological conditions experience extreme
suffering as their symptoms can quickly become overwhelming and unmanageable. Individuals
who experience difficulties mediating psychological symptoms can have difficulty obtaining
traditional employment and can potentially experience higher rates of homelessness or
incarceration.3
Patients with treatment-resistant psychological conditions continue to have difficulty with
symptom mediation. This paper will analyze the potential to reduce suffering in patients with
psychological conditions through therapeutic gene editing.
I.

Genetics and Psychological Conditions
Many patients diagnosed with psychological conditions do not obtain symptom relief.
This aspect comes as a result of psychological conditions that are treatment-resistant.
Traditionally, when patients present with a diagnosed psychological condition, they fall into one
of three categories:
1. The patient who has sought treatment and has no current symptoms
2. The patient who chooses not to receive medical interventions
3. The patient who has tried numerous medications and therapies but has obtained no relief
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Patients who have been correctly diagnosed with a psychological condition or a psychiatric
condition and have utilized two or more treatments for at least six weeks with no symptom
improvement are classified as treatment-resistant.4
The three categories of diagnosis, treatment, and eradication can be utilized to distinguish
genetic advancements in the field of psychology. When the diagnosis, treatment, and eradication
categories for genetic advancements are applied to treatment-resistant psychological conditions,
the potential to relieve suffering lies within the eradication phase.

a) Diagnosis
The diagnosis section utilized to categorize genetic advancements in psychological
conditions assists clinicians in diagnosing and recognizing psychological conditions before
symptoms present in the patient. Current research in genetics and psychological condition has
allowed researchers to determine various genetic associations that contribute to the likelihood of
developing a psychological condition.
Association studies have explored genetic associations present in individuals with
schizophrenia disorder. Single nucleotide polymorphism (SNP) is a significant genetic factor that
may increase an individual’s susceptibility to schizophrenia disorder. Numerous SNP locations
in a human leukocyte antigen (HLA) locus were explored in the Han Chinese population to
determine the genes that contribute to an individual’s susceptibility to schizophrenia disorder.5
This study indicates that the rs2021722 in the HLA locus could have a pathogenic relationship
with schizophrenia disorder.6 This data contributes to foundational knowledge for this disorder,
which builds a platform for future advancements for the etiology of schizophrenia disorder.
Researchers have similarly explored genetic risk loci associated with bipolar disorder. A
genetic locus is the specific location of a gene or DNA sequence on a specific chromosome.
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Genetic loci allow researchers to pinpoint the exact location of a gene to determine its nature and
responsibility within the human body. For example, one study suggests that there is a linkage
between the prevalence of bipolar disorder and the 4p16 and 16p13 genes.7 Similarly, a more
recent study found that there is an association between the DGKH, CACNA1C, and ANK3 genes
and bipolar disorder.8 While these genes have been independently linked to bipolar disorder,
these association studies have further contributed to our understanding of the genetic make-up of
this disorder and suggest a need for continued research in the field.
Researchers have not identified a specific genetic marker determining if a psychological
condition will be treatment-resistant. While researchers are unable to associate treatmentresistance with a particular gene, enhanced diagnostic abilities allow for early education for
individuals that may suffer from psychological conditions in the future.9 Early diagnosis can
assist an individual in determining the likelihood of transferring a genetically linked
psychological condition to their future children.10 For example, an individual may want to
receive genetic testing to determine if their child will have an extreme psychological condition.
In the future, genetic markers and genetic testing can assist in the early diagnosis of
psychological conditions and encourage mediation before symptoms become too problematic.
b) Treatment
Through genetic sequencing techniques, treatment methods and therapeutic interventions
can be targeted more efficiently and effectively in patients suffering with psychological
disorders. For example, pharmacogenetic techniques can be utilized to assist clinicians in
determining which medication will be most effective in patients with schizophrenia or bipolar
disorder. Through genetic sequencing of the patient, clinicians can utilize this technology to
individualize a treatment plan for each patient presenting with a psychological disorder.
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Additionally, pharmacogenetics can be utilized to determine which medications will have the
most negligible side-effects.11 Since medication compliance is challenging to attain for patients
suffering from psychological conditions, pharmacogenetics can predict which side effects will be
prevalent depending on the medication prescribed and the genetic make-up of the patient.
The pharmacogenetics of serotonin reuptake inhibitors (SSRIs) and the presence of
sexual dysfunction in patients was examined. Sexual disfunction as a result of SSRI use is
present in 20-70% of patients being treated for long-term depression.12 As a result of this
symptom, the patients willingness to comply with long-term medication protocols have been
influenced. As a result of this study, an association was found between serotonin and glutamate
system genes and the symptom of sexual disfunction.13 Side effect and symptom management
are crucial to consider when determining the most beneficial medication to treat a patient.
Through this type of pharmacogenetics clinicians are able to recognize potential side effects in
an attempt to limit their disturbances amongst the body.
In contrast, pharmacogenetics does not account for patients who experience treatmentresistant psychological conditions. Patients suffering from treatment-resistant psychological
conditions will not get any relief from the genetic advancements resulting from pharmacogenetic
research.14 Patients who were nonresponsive to pharmaceutical therapy will still not find relief
through pharmacogenetics. Pharmacogenetic solutions will not serve as a one-time cure for
psychological disorders. Each patient will require multiple drug administrations, and drug
adherence will still be crucial for patient recovery.
c) Eradication
The eradication category for psychological conditions is crucial to patients diagnosed with
treatment-resistant conditions. This conceptual model serves as an approach that allows patients
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with treatment-resistant psychological conditions to receive a source of mediation for their
suffering. The eradication phase for physical conditions involves therapeutic gene editing,
allowing patients to receive a one-time genetic correction for their illness or condition.
Therapeutic gene editing allows the patient to be cured of their condition and eliminates the
likelihood of the patient passing a genetic disease to their child.15 Therapeutic gene editing can
be utilized to eradicate psychological conditions entirely.
Therapeutic gene editing for eradicating genetically linked psychological conditions has
become increasingly researched in psychology. While researchers are not currently at a point
where psychological conditions can be pinpointed to one specific genetic risk loci, continued
research will advance clinicians' understanding of the disorders and will contribute to future
eradication methods. Although researchers cannot conduct therapeutic gene editing for
psychological conditions at this time, this method serves as the only real promise to mediate the
suffering experienced by patients with these treatment-resistant psychological disorders.
II.

Ethical Considerations
As researchers explore new niche aspects of therapeutic gene editing and new data is
obtained and published, the ever-changing discipline must continue to be examined. When
assessing the ethical principles in conjunction with therapeutic gene editing, the traditional
principles of beneficence, nonmaleficence and patient suffering are relevant for examination.16
a) Beneficence
The physician’s primary goal is to work to treat and improve the quality of life of their
patients. While the aim is to improve quality of life, the physician must weigh the probability of
risk and success with new and obscure clinical interventions. Advancements in medical
technology are currently produced by assessing various experiments' risks and benefits.
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Beneficence explores the clinician’s duty to improve psychological health or physical
health.17 Clinicians practice beneficence by diagnosing and treating a patient for their ailment.
For example, in genetics, beneficence would be practiced through a physician genetically testing
a woman for the BRCA1 and BRCA2 genes. If a positive test is obtained, the physician can offer
a double mastectomy to prevent future cancer development.18
In patients with psychological conditions, clinicians do aim to bring about improvements
in physical and mental health. While this is achievable for patients with traditional psychological
conditions, this is not attainable for treatment-resistant psychological conditions. Therefore,
resilient treatment options must be explored and implemented in patients with treatment-resistant
disorders. These options will work in the best interests of the patients being served and will bring
about the most significant improvements to the health of patients suffering from treatmentresistant disorders.
b) Nonmaleficence
Nonmaleficence aims to improve a patient’s physical and psychological health in a way
that reduces risk and prevents further harm.19 This ethical principle is similar to the portion of the
physician’s Hippocratic oath, which directs physicians to “do no harm”. Physicians can do no
harm by analyzing the side effects associated with a procedure or ensuring medical indications
are in place to suggest a procedure is necessary to improve the patient’s health.
Beneficence and nonmaleficence are best analyzed and assessed through benefit-risk
ratios. Benefit-risk ratios allow the physician to analyze the intended benefit of a medical
intervention and the perceived risks associated with a procedure. Physicians can then calculate if
the risk factors associated with an intervention are ethically justified.20 The benefit-risk ratios can
give physicians direction when assessing possible treatment plans for patients and allow for

7
patient involvement in medical decision-making. Additionally, these analyses can ensure that
physicians continue to do no harm and act in the patients’ best interests while assessing treatment
plans.
Physicians frequently encounter medical disorders that do not respond to conventional
treatment or require therapies that create tremendous side effects for the patient. In an attempt to
create the most beneficial treatment plan for the patient that incorporates the least amount of
harm, innovative treatment methods and procedures are necessary. Therapeutic gene editing
offers clinicians the ability to edit out genetic discrepancies before an illness ever occurs.21 This
methodology reduces or potentially eliminates pain and suffering due to psychological
conditions associated with a type of genetic origin. This treatment method ensures that patients
with treatment-resistant psychological conditions get mediation for the pain and suffering and are
not inflicted with additional treatment measures that are not medically indicated.
c) Potential to Reduce Suffering
The suffering in patients dealing with physical conditions and the suffering in patients
dealing with psychological conditions can be comparable in numerous aspects. To illustrate this,
consider treatment-resistant psychological conditions and terminal physical conditions. Patients
with terminal physical conditions experience extreme physical symptoms that can also bring
about psychological symptoms such as extreme depression or anxiety.22 As a result of these
symptoms, patients with terminal conditions, such as cystic fibrosis or cancer, have an increased
likelihood of experiencing job loss23 or strained relationships24 due to these unbearable
symptoms.
Patients with treatment-resistant psychological conditions have unbearable psychological
symptoms that frequently lead to the development of physical symptoms.25 For example,

8
common physical symptoms that may develop as a result of psychological conditions are
increased heart rate or difficulty breathing.26 As a result of these symptoms, these patients may
also experience strained relationships or job loss.
Where terminal physical conditions and treatment-resistant psychological conditions
differ is the mediation of the suffering resulting from the symptoms experienced by these
patients. Palliative care is a discipline that focuses primarily on comfort and supportive care.27
The palliative care service is traditionally utilized for any patient needing pain mediation for a
physical condition. Patients who have received a terminal diagnosis are typically referred to
either palliative or hospice care to receive symptom mediation and to make them comfortable
through a painful illness, whether it be terminal, a chronic condition, or just a severe recoverable
injury.
Patients dealing with treatment-resistant psychological conditions do not receive
palliative care services to assist with the extreme suffering they endure due to their disorder.
While the physical symptoms that the patient endures will be mediated, the psychological
symptoms will not be resolved. The patients dealing with treatment-resistant psychiatric episodes
receive basic therapeutic services without the long-term opportunity for symptom mediation.
Conclusion
As developments continue to be made in genetics, researchers become closer to
determining the definitive genetic sequences of psychological conditions. While significant
progress has been made in genetics, continued research is essential to understand the vast
contributions that genetics can make to the field of psychology.
While genetic sequencing aims to assist patients suffering from debilitating psychological
conditions, there is still a lack of mediation for patients dealing with these conditions. Given the
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suffering associated with treatment-resistant psychological conditions and the current lack of
mediation for these disorders, therapeutic gene editing should be considered to assist patients
with these conditions. Therapeutic gene editing offers patients with treatment-resistant
psychological conditions an opportunity to mediate their suffering and offers significant
improvements for future generations that have genetically linked psychological conditions in
their family history.
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